SFA-009

Drug discovery and biotech · by SFA Therapeutics, Inc.

Oral therapy for pancreatic cancer in combination therapy, currently in preclinical stage.

What it does

Oral therapy for pancreatic cancer in combination therapy, currently in preclinical stage.

  • Immune tolerance therapy for plaque psoriasis
  • Combination therapy for pancreatic cancer
  • Therapy for chronic liver disease to hepatocellular carcinoma
  • Therapies for rheumatoid arthritis and inflammatory bowel disease
Category
Drug discovery and biotech
Built for
Healthcare and life sciences
Users
Patients with psoriasis, Patients with autoimmune diseases, Patients with certain cancers
Public API
Not offered

Not yet disclosed: deployment options, platforms, languages and support channels.

Pricing

Pricing isn't published

SFA Therapeutics, Inc. doesn't list prices publicly. Ask them for a quote.

Security and compliance

No security details published yet

SFA Therapeutics, Inc. hasn't published certifications or security practices for SFA-009 that we could find. Ask their team for audit reports.

Reviews

No reviews yet

Reviews come from people who use SFA-009 at work. Share how your team uses it to help other buyers decide.

Alternatives

Is this your product?

Claim it to keep details accurate and submit evidence for the next ranking review.

Claim SFA-009